Vital Therapies Considers New Trial Of ELAD Liver Therapy After Trial Misses Endpoint
This article was originally published in Clinica
Vital Therapies, Inc. is assessing its options for moving forward with its stem cell-based bio-artificial liver therapy, ELAD, after the VTI-208 pivotal trial failed to meet its primary endpoint.
You may also be interested in...
The $800m sale of BTG Specialty Pharmaceuticals business to SERB leaves Boston Scientific with BTG’s successful interventional oncology and vascular products.
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.
Data from the EARLY AF First, Cryo-FIRST and STOP AF trials show cryoablation is a better option than drugs for patients with symptomatic atrial fibrillation.